The development of nanocarrier delivery systems opened new opportunities in the nano-technology field. Liposomes, possessing useful characteristics including their biocompatibility, stability in colloidal solutions and biodegradability are appropriate candidates for drug delivery applications. Vascular endothelial growth factors (VEGF) and their receptors (VEGFR) play a key role in the development of angiogenesis in physiological and pathological conditions such as wound healing and cancer, respectively. To overcome the delivery problems (e.g. drug half-life, cellular uptake, rate of release and efficacy) of VEGF/VEGFRs and their inhibitors, many studies focussed on the use of liposomes as nanocarrier drug delivery system. In this review we aim to describe the state-of-the-art targeting of VEGF/VEGFR and delivery of its inhibitors with liposomal nanocarriers. The lessons from this technology of liposomal nanocarriers should be instructive for scientists developing nano-encapsulation and delivery systems and those focussing on tissue engineering and innovative cancer therapy applications.

纳米载体传递系统的发展为纳米技术领域开辟了新的机遇。脂质体具有生物相容性、胶体溶液稳定性和生物降解性等有用特性，是药物递送应用的合适候选者。血管内皮生长因子 (VEGF) 及其受体 (VEGFR) 分别在生理和病理条件（如伤口愈合和癌症）中血管生成的发展中起关键作用。为了克服 VEGF/VEGFRs 及其抑制剂的递送问题（例如药物半衰期、细胞摄取、释放速率和功效），许多研究集中在使用脂质体作为纳米载体药物递送系统。在这篇综述中，我们旨在描述最先进的 VEGF/VEGFR 靶向及其抑制剂与脂质体纳米载体的递送。这种脂质体纳米载体技术的经验教训应该对开发纳米封装和递送系统的科学家以及那些专注于组织工程和创新癌症治疗应用的科学家具有指导意义。